A Single-Arm Open-Label Pilot Study of Combination Therapy of TACE and Ablation With Durvalumab in A Selected Hepatocellular Carcinoma Population at Intermediate Stage
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Durvalumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms TAD
- 30 Apr 2021 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.
- 30 Apr 2021 Planned primary completion date changed from 1 Aug 2024 to 1 Jun 2025.
- 30 Apr 2021 Planned initiation date changed from 1 Nov 2020 to 1 Jul 2021.